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Pathologists use loss of normal tissue
architecture as a key criterion to identify
and categorize disease states. Epithelia in
all glandular structures in vivo have
a characteristic organization where they
line a central lumen and are involved in
absorptive and/or secretory functions.
Under some physiological conditions—
such as pregnancy, wound healing, and
the periodic tissue remodeling that occurs
in tissues such as colon—there is a signif-
icant increase in the rate of cell prolifer-
ation. Although the proliferation rate in
these physiological conditions is higher
than that seen under disease states, the
overall tissue size and structure are
maintained. Such maintenance of size/
structure occurs because the increased
proliferation is tightly coupled with tissue
morphogenesis programs, resulting in
remodeling of normal tissue architecture.
Aberrant expression of drivers of prolif-
eration, such as growth factors, can induce
untimely proliferation of epithelia that
results in hyperplastic overgrowth of ducts
and alveoli. Despite the increase in cell
number, such overgrowth by itself is usually
not a cause for concern. However, when the
increase in cell number is coupled with
atypical changes in tissue architecture—such as
changes in the organization of epithelia
around a lumen, multilayering of the
epithelial lining in glandular structures, and
changes in cell size or shape—this is usually
a cause for concern. While pathways that
regulate cell proliferation have been intense-
ly investigated over the past decades, the
pathways that regulate cell architecture and
tissue organization are poorly understood.
DEAR1—A New Member of the
TRIM Family of Proteins
In this issue of PLoS Medicine, Ann
Killary and colleagues describe the dis-
covery and characterization of a new
tumor suppressor gene, ductal epithelium–
associated RING Chromosome 1 (DEAR1) [1],
that maps to Chromosome 1p35.1, a re-
gion of the chromosome that is associated
with loss of heterozygosity in breast and
other epithelial cancers [2]. The authors
also demonstrate that DEAR1 is mutated
in 13% of primary human breast cancers.
Thus DEAR1 is a frequently inactivated
gene in breast cancer.
DEAR1 is a member of the RING-B-
box-Coiled-Coiled (RBCC)/tripartite mo-
tif (TRIM) family of proteins. TRIM
proteins are expressed in response to
interferon signaling (for a review see [3]).
They have been implicated in a range of
biological processes related to innate
immunity. In addition, TRIM family
members are known to inhibit HIV virus
replication and are associated with genetic
disorders such as familial Mediterranean
fever (a disease associated with increased
inflammation). One family member, PML,
is an established tumor suppressor that is
associated with development of acute
promyelocytic leukemia.
All TRIM proteins have a RING domain
(see Glossary) in the N terminus [3]. While
the RINGdomain, observed in E3ubiquitin
ligases such as Cbl, was originally shown to
play a role in protein ubiquitination [4],
recent evidence shows that the RING
domain of PML interacts with a SUMO-
conjugating enzyme, UBE2I, suggesting that
RING domains may also mediate sumoyla-
tion [4]. How the TRIM proteins use these
domains and what pathways and biological
processes they regulate is not yet well
understood.
Most of the TRIM proteins localize to
the cytoplasm or the nucleus [3]. DEAR1
is the first member of the TRIM family
that localizes to the cell–cell junction,
which suggests that the TRIM proteins
are involved in processes that involve cell–
cell interactions.
DEAR1 Is a Predictive
Biomarker for Early Onset
Breast Cancer
Ann Killary and colleagues show that
DEAR1 is expressed in the ductal and
glandular epithelia of many adult tissues,
including breast, bladder, kidney, prostate,
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Linked Research Article
This Perspective discusses the fol-
lowing new study published in PLoS
Medicine:
Lott ST, Chen N, Chandler DS, Yang
Q, Wang L, et al. (2009) DEAR1 is
a dominant regulator of acinar
morphogenesis and an indepen-
dent predictor of local recurrence-
free survival in early-onset breast
cancer. PLoS Med 6(5): e1000068.
doi:10.1371/journal.pmed.1000068
Ann Killary and colleagues describe
a new gene that is genetically
altered in breast tumors, and that
may provide a new breast cancer
prognostic marker.
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mal breast epithelia express high levels of
DEAR1, the authors found that 70% of
ductal carcinoma in situ (DCIS) specimens
showed a loss or down-regulation of
DEAR1 expression. Such loss or down-
regulation suggests a role for DEAR1
during early stages of breast cancer.
Consistent with this possible role, the
researchers observed a mutation that
changes arginine at position 187 to
glutamine (R187Q) in both breast tumor
and adjacent normal epithelia. This mu-
tation was never seen in normal individ-
uals or in the single nucleotide polymor-
phism database, suggesting that mutation
of DEAR1 may be an early event that
occurs during the initial stages of transfor-
mation of normal epithelia.
Alterations in DEAR1 also show a strong
predictive value for future risk of aggres-
sive disease. The authors show that 56% of
DCIS stage I or II breast cancers in
premenopausal women aged between 25–
49 years show a complete loss of DEAR1
expression. Loss of DEAR1 expression
correlated strongly with family history of
breast cancer and with the development of
triple negative breast cancers. Together,
these observations identify DEAR1 as an
excellent predictive biomarker for early
onset breast cancers.
DEAR1 Is Implicated in
Epithelial Biology and
Carcinoma
When cultured on a bed of extracellular
matrix (such as Matrigel), normal mam-
mary epithelial cells form three-dimen-
sional acini-like structures with a layer of
polarizedepithelialcellssurroundingacen-
tral hollow lumen. In Killary and col-
leagues’ study, down-regulation of DEAR1
in normal mammary epithelial cells result-
ed in formation of aberrant acinar struc-
tures with decreased rates of apoptosis and
a loss of normal cell polarity. Down-
regulation of DEAR1 did not have any
effect on proliferation of these normal
mammary epithelial cells, showing that
DEAR1 regulates cell architecture path-
ways independent of any effect on cell
proliferation.
Breast cancer–derived cells are known
to form irregular multiacinar structures in
vivo [5]. In the new study, re-expression of
DEAR1 restored these cells’ ability to form
normal single acini with central empty
lumen and a layer of polarized epithelial
cells. Here again, re-expression of DEAR1
did not have a significant effect on the cell
proliferation rates, showing that DEAR1 is
a critical regulator of 3-D epithelial
morphogenesis. Transformation of 3-D
organized structures in breast cancer is
thought to occur due to a coordinated loss
of control over cell proliferation, cell
death, and cell polarity pathways. Howev-
er, several previous studies have shown
that cell proliferation pathways are not
always coupled to cell polarity and cell
death pathways [6–9]. Killary and col-
leagues’ study supports the concept that
cell polarity and cell proliferation path-
ways are uncoupled in mammalian epi-
thelial cells. Further analysis will be
required to identify the targets of DEAR1
and the mechanism by which DEAR1
regulates cell architecture.
DEAR1 and CHD5: Two Pieces in
a Puzzle
DEAR1 maps close to another tumor
suppressor, CHD5, which was recently
mapped to Chromosome 1q by a chromo-
some engineering approach [10]. With the
identification of DEAR1 we are beginning
to develop a deeper understanding of the
molecular basis for the loss of Chromosome
1q in human cancers. While CHD5
regulates cell proliferation pathways by
increasing expression of the cell cycle
inhibitor p16/ink4a locus, DEAR1 regu-
lates cell architecture. It is possible that
CHD5 and DEAR1 represent the two sides
of the transformation process, where loss of
CHD5 results in aberrant proliferation
while loss of DEAR1 results in loss of tissue
architecture, and the combination of the
events can drive changes in the epithelial
tissues that can progress towards cancerous
growth. It would be interesting to deter-
mine the effect of combined loss of CHD5
and DEAR1 both for clinical prognosis and
during transformation of epithelial cells in
culture and animal models.
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CHD5: Chromodomain helicase DNA binding protein 5.
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